Parathyroid hormone-related peptide analogue
Abaloparatide
An approved bone-anabolic peptide with fracture outcome evidence in defined osteoporosis populations and product-specific safety limits.
Also known as Tymlos · BA058 · PTHrP analogue
01 · Evidence profile
One molecule, four evidence questions
The ACTIVE phase 3 trial supports fracture-risk reduction in postmenopausal women with osteoporosis.
Approved labeling characterizes PTH1-receptor activity, exposure, and bone-turnover effects.
Known risks and monitoring are described in the current product label.
High for authentic Tymlos used within the approved label.
02 · Identity
What it is
Abaloparatide is a synthetic analogue of parathyroid hormone-related peptide that activates the PTH1 receptor and is used as a bone-anabolic medicine.
03 · Product identity
The molecule is not the finished product.
Tymlos is a product-specific prescription medicine. Trial findings do not validate unapproved PTHrP analogues or general performance use.
Tymlos
2025 label- Formulation
- Injection pen
- Route
- Subcutaneous
- Indication scope
- Osteoporosis uses in the high-fracture-risk populations defined in the product label.
- Tymlos
- Osteoporosis treatment or bone-density increase in labeled high-risk populations
04 · Evidence snapshot
What the evidence can and cannot say
ACTIVE randomized postmenopausal women with osteoporosis to abaloparatide, placebo, or open-label teriparatide. Abaloparatide reduced new vertebral and nonvertebral fractures versus placebo over 18 months.
The result does not establish universal superiority over every osteoporosis medicine, enhancement in healthy people, or improved healing of every acute injury.
05 · Claim check
Three claims under the lens
“Abaloparatide reduced fractures in a randomized phase 3 trial.”
ACTIVE found fewer new vertebral and nonvertebral fractures versus placebo in postmenopausal women with osteoporosis.
- Evidence basis
- Randomized human outcomes
- Scope
- Postmenopausal women with osteoporosis at fracture risk over 18 months.
“Abaloparatide is proven to improve bone outcomes in every population.”
Approved indications and trial populations define the evidence boundary.
- Evidence basis
- Randomized human outcomes
- Scope
- Populations outside the current label and pivotal trial.
“An anabolic bone effect means abaloparatide is a safe performance enhancer.”
A prescription osteoporosis benefit-risk assessment does not establish safe enhancement in healthy people.
- Evidence basis
- Regulatory or product record
- Scope
- Healthy or athletic performance use.
06 · Safety boundary
Before this becomes personal
This is a prescription osteoporosis medicine with product-specific warnings and use limits. No dose, injection, or performance guidance is provided.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed 2026-07-23. This status is not personal clearance to compete.07 · Sources
Check the primary record
08 · Provenance
Review history
Initial brief based on the 2025 Tymlos label and ACTIVE phase 3 trial.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.